COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms COSIMO
- Sponsors Bayer
- 12 Feb 2018 Planned End Date changed from 15 Dec 2018 to 15 Mar 2019.
- 12 Feb 2018 Planned primary completion date changed from 15 Aug 2018 to 15 Nov 2018.
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.